This clinical trial studies the use of fluciclovine (18 fluorine [F]) positron emission tomography (PET)/computed tomography (CT) in predicting treatment response in patients with hormone-resistant prostate cancer that has come back or spread to other places in the body and are receiving chemotherapy. Fluciclovine (18F) is a radiotracer that accumulates in tumor cells and may be useful in imaging tumors using PET scans. PET/CT scans make detailed, computerized pictures of areas inside the body where fluciclovine (18F) accumulates. Diagnostic procedures, such as fluciclovine (18F) PET/CT, may help doctors predict treatment response in patients receiving chemotherapy.
I. To determine if uptake on fluciclovine (18F) (anti-3-[18F]FACBC) PET-CT in metastatic lesions with castration resistant prostate carcinoma is affected by chemotherapy.
II. To determine if response on anti-3-[18F]FACBC PET scan after 1 and 4 cycles of chemotherapy correlates with clinical and imaging response after 4 cycles of chemotherapy as measured by standard parameters including prostate specific antigen (PSA) and routine objective measurements.
III. To determine if response on anti-3-[18F]FACBC after 1 and 4 cycles of chemotherapy correlates with clinical and imaging response to therapy at one-year as measured by standard parameters including routine objective measurements, PSA progression, clinical progression, and mortality.
I. To determine if uptake on the baseline anti-3-[18F]FACBC PET-CT correlates with response to chemotherapy after 4 cycles and at one year as measured by standard parameters.
Patients receive fluciclovine (18F) intravenously (IV) over 1-2 minutes and then undergo PET/CT at baseline, within 7 days of the completion of the first course of chemotherapy*, and within 14 days of the completion of the fourth course of chemotherapy.
*Note: Patients receive docetaxel IV on day 1 and prednisone orally (PO) twice daily (BID) every 21 days for 4 courses.
After completion of study, patients are followed up for at least 1 year.